Objectives: There is currently conflicting level 1 evidence in the use of long-term antibiotics for chronic rhinosinusitis without nasal polyps. The primary aim of this feasibility study was to optimise future randomised trial design by assessing recruitment and retention of patients alongside providing preliminary data on symptomatic control. Design: Prospective, multicentre feasibility (cohort) study with all patients receiving macrolide therapy for 12 weeks and a further subsequent 12-week follow-up. Participants received a 12-week course of clarithromycin 250 mg alongside twice daily topical mometasone and nasal douching. Primary outcomes focused on recruitment, retention and compliance. Clinical and quality-of-life outcomes measures were also recorded. Setting: Patients were prospectively recruited from six UK outpatient clinics. Participants: Adult patients with chronic rhinosinusitis without nasal polyps and no prior endoscopic sinus surgery underwent baseline assessment and then follow-up at 3 and 6 months. Main outcome measures: Six-month recruitment and retention data. Results: Over 13 months, 55 adults were recruited from five centres. Four patients declined participation. 75% of patients were retained within the study. Dropouts included one medication contraindication, three unable to tolerate medication and 10 not attending full follow-up. Sino Nasal Outcome Test-22 and endoscopic scores showed statistically significant improvement. No other clinical or quality-of-life assessment improvements were seen. Conclusion: Retention and recruitment to a trial using long-term clarithromycin to treat chronic rhinosinusitis without nasal polyps is achievable and this data will support a future randomised controlled trial. The study provides vital insight into trial design, thus informing UK research networks and rhinology researchers internationally.
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Long-term macrolide therapy is recommended in the treatment of chronic rhinosinusitis (CRS). 1 Its potential benefits were extrapolated from findings in the respiratory community where marked improvement in both chest and nasal symptoms was seen in patients with panbronchiolitis alongside prolonged survival rates. 2 The anti-inflammatory effects of reducing cytokine activity and in turn reducing airway inflammation and mucus production are well documented. 3 In CRS, there have only been two randomised controlled trials (RCT) performed to date which show conflicting evidence; the efficacy of macrolides in treating the condition has been called into question due to this conflicting level 1 evidence. 4, 5 The first double-blind RCT published showed a significant improvement in clinical scores (alongside other outcomes) with roxithromycin in CRS without nasal polyps (CRSsNPs), particularly in the normal IgE subgroup. 4 A second RCT with a similar number of patients, using azithromycin did not show a significant improvement between the macrolide and placebo groups. 5 The Cochrane review into antibiotics for CRS concluded that Wallwork et al.'s study supported the therapy, but further large sample studies were required. 6 This was echoed in a recent metaanalysis which found limited data to support macrolide therapy in CRS, 7 stating further research is required. In addition, it is recognised that the data from the most recent RCT 5 may skew outcomes as the study recruited predominantly patients who had failed previous sinus surgery, and included mixed phenotypes, with both CRSwNP and CRSsNP. Potentially, more patients with elevated IgE levels who may not respond to macrolide therapy were recruited, although subgroup analysis was not performed. 1 With the increasing emergence of antibiotic resistance, it is important that clinicians use such medications responsibly. 8 In addition, clarithromycin use is associated with an increased risk of cardiac death particularly in women; 9 hence, evaluation of its use especially in long-term therapy is essential.
A future RCT to clarify the use of macrolides in CRS must be sufficiently powered, use appropriate clinical assessment methods and ensure retention of patients leads to meaningful data collection. To inform this process, we conducted a UK-based, multicenter feasibility study. The primary outcome measures were patient recruitment and retention to the study with secondary outcomes including assessment of medication tolerance and compliance to the study protocol. In addition, feedback and clinical outcomes of the study are reported.
Materials and methods

Ethical considerations
Ethical approval was given to the study from the West Midlands Research Ethics Committee (reference: 12/WM/ 0359), and the study was included on the UK CRN portfolio (ref: 13417).
Methods
The study was conducted as a multicentre collaboration between six sites. Study centres included James Paget University Hospital (Great Yarmouth), Guys & St Thomas Hospital (London), Royal Surrey County Hospital (Guildford), Queens Medical Centre (Nottingham), Freeman Hospital (Newcastle) and Queen Elizabeth Hospital (Birmingham). As this was a feasibility study, no sample size was needed but a target recruitment of 50 patients over a 12-month period was established at the beginning. At the beginning of the study, the chief investigator hosted a teleconference with principal investigators and research nurses at all sites included. 10 Participant flow. Patients diagnosed with CRSsNPs were recruited from the outpatient clinics at participating sites and subsequently underwent two face-to-face study visits and a third interaction via postal correspondence (questionnaires and feedback only). Patients who completed the study were asked to comment on their participation in the trial (Appendix 1). Baseline clinical assessment included endoscopy (scored using the Lund-Kennedy endoscopic score, 11 mucociliary clearance testing (saccharin test), smell testing (Sniffin' sticks), serum IgE levels, skin prick allergy testing and sinus CT with Lund-Mackay scoring. 12 All but the last three tests were repeated at visit 2 following the 12-week course of clarithromycin. The sinonasal outcome test (SNOT-22 -a disease-specific measure of HRQOL), SF-12 and EQ-5D questionnaires (both global measures of HRQOL. [13] [14] [15] ) were completed at all three encounters.
Statistical analysis
Statistical analysis of continuous variables was performed using paired t-tests and nonparametric tests used for noncontinuous data. In regard to SNOT-22 scores, patients with a minimum clinical difference of nine points on the SNOT-22 were considered to have had a clinical improvement in symptoms. 16 
Results
Primary outcome measures
Recruitment of patients. Over a 13-month period (January 2013-January 2014), 55 patients were recruited from five units, 51% were male and the mean age was 55 years (range from 21 to 81). Sixty-three patients were eligible but eight declined. Despite ethical approval being confirmed in November 2012, it took until the following December for all six sites to finally complete research governance. At three sites, Research & Development offices chose to interpret the research protocol differently from the ethics committee resulting in a temporary suspension of the study for 2 weeks while the Medicines and Health Regulation Authority (MHRA) confirmed the study was not a Clinical Trial of an Investigational Medicinal Product (CTIMP). During the first 9 months of the study, only the lead site was open to recruitment leading to considerably different numbers of patient participating in each site ( Table 1) .
Retention of patients. At the recruitment stage, one patient was excluded during preliminary work-up as clarithromycin was found to be contraindicated although underwent all of visit 1 before this was identified. Three further patients were unable to take the full course of clarithromycin due to side-effects and 10 patients dropped out (Table 1) . Compliance with the study protocol fell towards the end of the study with 55 patients attending visit 1, 45 attending visit 2 and 41 completing visit 3. Recruitment and retention rates varied considerably between hospitals, as shown in Table 1 .
Compliance with assessment and treatment. Adherence to the study protocol varied between sites with poor compliance of the research staff in performing some clinical tests ( Table 2 ). The use of the Sniffin' sticks was temporarily halted during the study due to confusion about their use (by the sponsor representative) and subsequently their status at MHRA, but this was later overturned and their use reinstated. The reasons for poor compliance to the protocol are varied, and feedback from research nurses taking part is shown in appendix 2. Logistical issues affected some sites, for example difficulty getting hold of equipment [in particular Sniffin' sticks kit (Burghart Messtechnik GmbHTinsdaler Weg 175D-22880 Wedel, Germany)]. In addition, poor conduct of the compulsory elements of the protocol in one centre was noted.
Medication tolerance and compliance. Three patients suffered adverse effects during taking the medication (acid reflux, skin reaction, gastrointestinal symptoms) and a fourth had headaches for the first 2 weeks which resolved enabling full completion of the 12-week course.
Secondary outcomes
Patient feedback. Twenty-six patients responded to the postal questionnaire: 18 patient patients reported no negative aspects; the same number of patients would be happy to take part in a placebo study. Three patients reported issues with the clinical testing (discomfort during mucocilary clearance and Sniffin' stick testing). Constructive criticism regarding communication between the study centre and patients/GP was also made. Patients also raised the question about the possibility of breaking the blinding process if there was no symptomatic improvement in a placebo-controlled trial.
Staff feedback. It came apparent during running the trial that experience of the research nurses (RN) involved in the trial was of differing levels from an experienced ENT trained RN (site 1), to experienced (but not ENT trained) RN (site 3), to inexperienced RN (site 6). There were issues with implementation of the protocol, specifically using upto-date questionnaires and performing the compulsory tests. Unofficial feedback from clinicians also highlighted the fact that some RNs were unfamiliar with certain clinical tests (Sniffin' sticks) and the length of time this took to perform such aspects reflected negatively on patient recruitment (seen at site six where the RN actively discouraged patients from taking part due to the perceived time to perform the test).
Clinical outcomes. Table 3 shows the clinical results from this feasibility study. Excluding the four patients unable to take their medication due contraindications/side-effects, 45 and 41 patients completed all surveys at visits 2 and 3, respectively. Statistically significant reduction in SNOT-22 scores was found at both 3 and 6 months. This was clinically significant (score reduction of nine points or greater 16 ) in 22 of 45 and 20 of 40 patients at 3 and 6 months, respectively. Endoscopic scores also showed a statistically significant improvement. Positive mucopus culture was seen in 12 patients as baseline assessment.
No other statistically significant result was seen in other clinical outcomes of mucocilary clearance and smell testing. Serum IgE levels were recorded in 50 patients at visit 1 and 43 patients had both IgE levels and 12-week SNOT-22 data (Table 4) . A greater proportion of responders to therapy were seen in the patients with elevated IgE levels although this was not significant (69% versus 47%; P = 0.212) in contrast to the previous RCT. 5 Low levels of inhalant screen positivity were seen in allergy testing (performed in 51 patients overall, 50 of whom has RAST and one skin prick testing), nine patients demonstrated inhalant screen positivity and five of such patients had elevated IgE also.
Lund-Mackay (LM) scoring of CT paranasal sinuses was performed in 54 patients. There was no significant correlation between LM score and symptomatic improvement following treatment using the clinically significant SNOT-22 score (P = 0.636). At site 1, the number of patients progressing to surgery was 12 of the 35 patients (34%) completing the study (11 undergoing sinus surgery and one undergoing septoplasty).
Patient-reported outcomes. EQ-5D analysis showed no statistical difference in either mean VAS score or any of the five health dimensions (Fig. 1a-e) although patients reported higher rates of pain/discomfort and anxiety/depression. SF-12 scores (both mental and physical components) increased at both visits 2 and 3 from baseline. The improvements were modest and did not improve to that above the score expected for a 'typical adult'.
Discussion
Synopsis of key findings
We aimed to investigate the feasibility of a 6-month trial where clarithromycin was given for 12 weeks, showing a recruitment rate of 83% and a retention rate of 76%. There was an average recruitment rate of 4.23 per month across all sites in the latter part of the study. Compliance to the study protocol varied from site to site, specific issues regarding this 14 16 are discussed below. The lead site recruited significantly more patients (recruitment rate of 3.17/month) with good retention rates of 92%, and the results are somewhat skewed by the poor retention rates in some other centres. This initiates a discussion about factors that contributed to the variation seen and how these could be managed to improve overall study retention and data collection. Recognising these issues is vital in planning a future RCT.
Comment on recruitment, retention and study protocol
The results show a failure of comprehensive data collection at all sites. An incorrect version of one study questionnaire was uploaded onto the central study site at the start of recruitment which caused some understandable confusion. At one centre, the RN misinterpreted the requirement to perform other outcome measures from the protocol, hence reducing clinical and questionnaire outcomes further. At another site, eight patients identified by initial screening failed to consent after assessment with an inexperienced generic research nurse, and no patients at this site ever joined the study. Time to perform outcome tests was cited as the greatest barrier to participation. It is notable that the RN at this site took over 45 min to perform olfactory testing, compared to 20 min by an experienced research nurse. Lastly, the reduced number at some sites was in part due to significant delays in research governance approval, meaning some centres were unable to recruit until the last 4 months. These difficulties were in stark contrast to the lead site which had an experienced research nurse with an ENT background who successfully recruited patients to the study throughout the 13-month duration with the loss of only three patients (two due to drug side-effects and one dropout). The experience of the research nurses at the individual sites had a big impact on their ability to both recruit patients and perform the relevant investigations, despite a teleconference at the beginning of the study to talk through the flowchart. This has demonstrated a clear need for a specific training day for all research nurses involved in any future trial. Research nurse support provided by UK local clinical research networks (LCRNs) is often generic in nature but will vary from site to site. Any future RCT would include a study training day to ensure all staff undergo standardised training and has also inspired a national ENT study day for all generic research nurses. Due to the limited funding for this study, a centralised database was not available, but this would be mandatory if a formal RCT is funded in due course, to allow for ease of secure data entry at site visits. This feasibility study has identified significant issues for reflection if a full-scale RCT is to be conducted effectively. In addition, 93% patients were able to take the full course of therapy without significant side-effects with only three subjects unable to Fig. 1. (a-e) The EQ-5D data is presented as percentage of patients reporting each level in each of the five dimensions at the three separate visits. Patients were self-caring, with good mobility (level 1) but had higher rates of problems with anxiety/depression and pain/discomfort. The two latter dimensions worsened in some patients at 6 months. baseline-black; 3 months-dark grey; 6 months-light grey.
Feasibility study of long-term macrolides in CRS 135 tolerate clarithromycin and with appropriate screening, no serious adverse events, despite concerns from recent publications. 9 There is a growing body of evidence (published after study design) that macrolide therapy in those with previous ischaemic heart disease or prolonged QT interval on ECG is associated with cardiac toxicity. While no patients in this feasibility study suffered such side-effects, the cohort was small, and hence, any future RCT should exclude patients with such risk factors and include an ECG in pretreatment investigations.
17,18
Clinical results and comparison to other studies It must be emphasised that this is not a placebo-controlled trial and that without a control arm, the effect of intranasal corticosteroids and douching cannot be assessed. While the clinical results from this case cohort study suggest that a longer-term course of macrolide therapy may be therapeutically advantageous in up to 50% of patients with CRSsNPs, no firm conclusions regarding clinical effectiveness can be made without a control arm. However, the response rate seen in this feasibility study provides valuable information for trialists considering a formal RCT, as it can inform power calculations. In addition, it is notable that no other clinical indicators (e.g. mucocilary clearance, smell testing) nor generic quality-of-life assessment showed any statistically significant improvement. The results support the need for a further RCT as suggested by a recent meta-analysis 7 which found limited data to support such therapy. In addition, within the wider medical community it is vital to ensure long-term macrolides are used responsibly in the face of increasing antimicrobial resistance.
This study was designed to capture potential issues prior to recruiting to a full-scale RCT. Limitations in study design can be acted upon at this early stage, such as the limited data collected to assess patient compliance with medication. The study relied purely on patient self-reporting and in the future questionnaires/diaries could be used to clarify this further. As patients also raised concerns regarding the time taken to complete outcome assessments, the number of outcome measures should be re-evaluated prior to a formal RCT to minimise participant burden and maximise recruitment. Encouragingly many patients reported positive experiences regarding study involvement and were happy to take part in a placebo-controlled trial.
Conclusion
This paper presents an honest account of the issues encountered when conducting a multicentre clinical trial. The issues identified have been integral in informing study design for a future RCT into macrolide therapy. In addition, we are keen to share our experiences with other researchers in order to reduce research waste through poor recruitment and retention which can lead to both underpowered and/or unfinished trials. This is in keeping with advice in avoiding research waste as identified by Chalmers and Glasziou. 19 Clinical trials require extensive time and financial commitment. It is the responsibility of researchers to ensure patients who relinquish their time to participate in trials are recruited to well-designed, well-conducted studies; a feasibility study is an essential part of this process. The research team have recently been awarded a Programme Grant from the National Institute of Health research that will include a trial to assess the role of longterm antibiotics.
Keypoints
• A randomised controlled trial of clarithomycin versus placebo should be feasible based on the recruitment and retention seen in this study.
• In order to maximise the potential for trial retention, research nurses at all sites need to be fully engaged with the trial processes and provided with suitable training in ENT outcome measures.
• Long-term macrolide therapy has the potential to benefit patients with CRS without polyps in up to 50% of cases but this needs corroborating with a formal RCT.
3 1 patient felt dizzy and faint with smell test, don't like filling in questionnaires. 4 'Slight improvement on tablets now back to how I was before' 5 'The tests were fine but I thought the questionnaire could have included 'other symptoms' e.g. headaches, which was one of the worse aspects for me' 1 patient said 'there needs to be better communication between the hospital and GP surgery, as the GP thought the antibiotics were study medication and didn't need to supply them'. Another patient felt the instructions given were not clear/ incorrect, specifically: 1 his nasonex prescription had the incorrect frequency on (od instead of bd), 2 he wasn't informed to continue his douching and nasal spray when the antibiotics finished (could this be put into the patient instructions. 3 2 CT scans before and after would be better 4 he felt a longer follow up period would be beneficial, incorporating each season maybe. When asked if he would have participated if there was a chance of receiving a placebo, he said yes -but -'if there was no improvement in symptoms would the blinding be broken and then he gets a prescription for antibiotics if it was shown he had the placebo?' If this wasn't the case then he may not participate. 2 patients mentioned this point.
